Cargando…
ROR2, a driver of “phenotype switching” in melanoma?
Receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a receptor for the Wnt5a ligand that was shown to play a dual role in cancer. ROR2 was shown to either suppress or promote tumor progression in different tumor types by regulating the same biological processes (i.e. proliferation, invasion) i...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487041/ https://www.ncbi.nlm.nih.gov/pubmed/36127680 http://dx.doi.org/10.1186/s12935-022-02711-x |
_version_ | 1784792408654872576 |
---|---|
author | Lopez-Bergami, Pablo |
author_facet | Lopez-Bergami, Pablo |
author_sort | Lopez-Bergami, Pablo |
collection | PubMed |
description | Receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a receptor for the Wnt5a ligand that was shown to play a dual role in cancer. ROR2 was shown to either suppress or promote tumor progression in different tumor types by regulating the same biological processes (i.e. proliferation, invasion) in opposite ways. We have recently observed that ROR2 plays multiple and somewhat contradictory roles in melanoma where it impairs cell proliferation but promotes migration, EMT and chemoresistance. In the present article, ROR2 is proposed to be a major driver of “phenotype switching” in melanoma that can tilt the cellular behavior toward proliferative or invasive phenotypes. This function of ROR2 has therapeutic implications since it would provide an opportunity for targeting specific phenotypes such as invasive and drug-resistant ones by inhibiting ROR2. |
format | Online Article Text |
id | pubmed-9487041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94870412022-09-21 ROR2, a driver of “phenotype switching” in melanoma? Lopez-Bergami, Pablo Cancer Cell Int Hypothesis Receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a receptor for the Wnt5a ligand that was shown to play a dual role in cancer. ROR2 was shown to either suppress or promote tumor progression in different tumor types by regulating the same biological processes (i.e. proliferation, invasion) in opposite ways. We have recently observed that ROR2 plays multiple and somewhat contradictory roles in melanoma where it impairs cell proliferation but promotes migration, EMT and chemoresistance. In the present article, ROR2 is proposed to be a major driver of “phenotype switching” in melanoma that can tilt the cellular behavior toward proliferative or invasive phenotypes. This function of ROR2 has therapeutic implications since it would provide an opportunity for targeting specific phenotypes such as invasive and drug-resistant ones by inhibiting ROR2. BioMed Central 2022-09-20 /pmc/articles/PMC9487041/ /pubmed/36127680 http://dx.doi.org/10.1186/s12935-022-02711-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Hypothesis Lopez-Bergami, Pablo ROR2, a driver of “phenotype switching” in melanoma? |
title | ROR2, a driver of “phenotype switching” in melanoma? |
title_full | ROR2, a driver of “phenotype switching” in melanoma? |
title_fullStr | ROR2, a driver of “phenotype switching” in melanoma? |
title_full_unstemmed | ROR2, a driver of “phenotype switching” in melanoma? |
title_short | ROR2, a driver of “phenotype switching” in melanoma? |
title_sort | ror2, a driver of “phenotype switching” in melanoma? |
topic | Hypothesis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487041/ https://www.ncbi.nlm.nih.gov/pubmed/36127680 http://dx.doi.org/10.1186/s12935-022-02711-x |
work_keys_str_mv | AT lopezbergamipablo ror2adriverofphenotypeswitchinginmelanoma |